Harnessing AI for Enhanced Cancer Care: Current Applications and Future Prospects

Subhajit Roy[1]*, Payal Guha[2] and Debapriya De[3]

[1,2,3]*Department of Biotechnology, Brainware University, West Bengal, India.*
**Corresponding Author. Email: mr.sroy2002@gmail.com*

Abstract

Artificial intelligence (AI) is profoundly transforming the field of oncology, offering significant advancements in cancer care, including diagnostics, treatment planning, and patient management. Currently, AI applications in oncology span several critical areas. Advanced diagnostic tools leverage AI algorithms, particularly deep learning, to analyze medical images like radiographs, CT scans, and MRIs, enabling early and accurate cancer detection. Predictive analytics and AI models are used to foresee patient outcomes by examining extensive data, including genetic information, tumor characteristics, and clinical records, thereby enabling personalized treatment plans. AI's role in personalized medicine is also notable; by integrating data from various sources, AI recommends specific treatment regimens tailored to individual patients, enhancing treatment efficacy and reducing adverse effects. Furthermore, AI aids in optimizing radiation therapy by improving dose distribution to target tumors more effectively while sparing healthy tissues. In drug discovery, AI accelerates the process by analyzing vast datasets to identify potential therapeutic targets and predict new compounds' efficacy, thus speeding up the introduction of new cancer treatments. Additionally, AI tools are improving patient management by monitoring symptoms, managing treatment side effects, and providing psychological support through AI-driven chatbots and mobile applications.

Looking to the future, AI holds immense potential in oncology, promising to integrate multidisciplinary platforms for comprehensive cancer care, address the challenges of rare tumours, and support drug discovery and development further. As AI technology evolves, it is poised to transform oncology, making cancer care more efficient, effective, and personalized, ultimately leading to better patient outcomes and a deeper understanding of cancer biology. These ongoing advancements underscore the potential of AI to significantly reduce the global burden of cancer and revolutionize the field of oncology.

***Keywords:** AI in oncology, Cancer diagnostics, Treatment planning, Medical imaging, Predictive analytics, Personalized medicine, Drug discovery, Symptom monitoring.*

Figure 1. AI in Cancer Detection

1. Introduction

Cancer remains one of the most formidable challenges to global health, accounting for approximately 10 million deaths in 2020 alone (Sung et al., 2021). Despite substantial advancements in screening and therapeutic modalities, the heterogeneity of tumors, complex genetic interactions, and varied patient responses continue to hinder optimal outcomes (Topol, 2019). Current clinical decision-making often relies on subjective human interpretation, which can introduce diagnostic variability and therapeutic inefficiency. Recent data from the *World Health Organization (2023)* and *Global Cancer Observatory (GLOBOCAN 2022)* highlight a projected 47% increase in new cancer cases by 2040, emphasizing the urgent need for more reliable, automated, and personalized diagnostic and treatment systems. This represents a significant research gap—traditional cancer management frameworks are insufficient to handle the massive scale and complexity of biomedical data generated in modern oncology.

Artificial Intelligence (AI) has emerged as a transformative solution capable of addressing this gap. AI techniques such as machine learning (ML), natural language processing (NLP), and deep learning (DL) can process vast, multi-dimensional datasets—including genomics, pathology, and imaging—far beyond human capability (Ching et al., 2018; Erickson et al., 2017). These systems not only enhance diagnostic precision but also support personalized treatment planning, predictive modeling of outcomes, and accelerated drug discovery (Esteva et al., 2021; Jiang et al., 2021). The current study aims to explore how AI is revolutionizing cancer diagnosis, treatment, and patient management, while highlighting key limitations and ethical challenges that must be addressed for clinical translation. This synthesis provides a comprehensive review of AI's contributions to oncology and outlines the future directions for achieving safer, interpretable, and equitable cancer care.

2. Enhanced Diagnostic Accuracy

Artificial Intelligence (AI) is making significant strides in enhancing the diagnostic

accuracy of cancer by utilizing advanced algorithms and extensive datasets to meticulously analyze medical images and genetic information. AI systems possess the remarkable capability to detect subtle patterns and anomalies that might easily be overlooked by human clinicians, thereby facilitating earlier and more precise diagnoses. For instance, AI-powered tools have demonstrated remarkable success in accurately identifying malignant tumors in mammograms and other imaging scans, achieving higher accuracy rates than traditional diagnostic methods. This advancement not only leads to improved patient outcomes by enabling timely medical interventions but also significantly reduces the likelihood of both false-positive and false-negative results. Consequently, the entire diagnostic process becomes more streamlined and efficient, offering substantial benefits in the early detection and treatment of cancer.

2.1 AI in Medical Imaging

The integration of Medical Imaging with Artificial Intelligence (AI) has led to remarkable advancements, particularly through the application of Convolutional Neural Networks (CNNs). For instance, the study conducted by McKinney et al. (2020) highlighted that AI models demonstrated significantly superior diagnostic performance in detecting breast cancer in mammograms compared to radiologists. This improvement not only enhances the accuracy of breast cancer diagnosis but also underscores the potential of AI in medical imaging.

Moreover, AI technology has proven to be indispensable in the screening of lung cancer. Ardila et al. (2019) utilized Deep Learning (DL) models to identify pulmonary nodules with greater sensitivity and specificity than traditional methods. This approach ensures more accurate detection and assessment of lung cancer, thereby facilitating early intervention and treatment. The advancements in AI-driven medical imaging exemplify the profound impact of combining cutting-edge technology with medical expertise, paving the way for more precise and reliable diagnostic processes.

Figure 2 Workflow of AI-Driven Cancer Diagnosis Using Medical Imaging and Histopathology Analysis

2.2 Histopathology and Digital Pathology

In digital pathology, the role of AI's role rapidly improving day by day. Coudray et al. (2018) utilized a deep learning approach to distinguish the subtypes of Lung Cancer with high accuracy. In case of Prostate Cancer, Bulten et al. (2020) demonstrated that AI-based image analysis not only could devotedly categorized tumors, but also minimizes the variability of inter-observer. These developments focus on the capability of AI to efficient diagnostic workflows, upgraded accuracy and even reduced amount of turnaround times.

However, interpretability remains a crucial consideration. Many deep learning systems function as "black boxes," providing predictions without transparent reasoning. Thus, explainable AI (XAI) approaches are increasingly emphasized to ensure clinical reliability and regulatory acceptance (Holzinger et al., 2022).

The rapid evolution of AI in diagnostic oncology has not only enhanced the accuracy of disease detection but has also laid the groundwork for predictive intelligence in clinical decision-making. Once diagnostic models identify the cancer type and stage, predictive analytics leverages these outputs—alongside molecular, histopathological, and clinical parameters—to forecast disease progression, treatment response, and patient survival. This seamless transition from

detection to prediction signifies a paradigm shift from reactive to proactive oncology, enabling truly personalized and preemptive patient care.

3. Predictive Analytics and Prognostication

Predictive analytics has emerged as one of the most promising applications of Artificial Intelligence (AI) in oncology, enabling clinicians to forecast disease progression, treatment response, and survival outcomes with remarkable precision. By analyzing vast datasets that integrate clinical, radiomic, and genomic information, AI models can identify complex, non-linear patterns that are often indiscernible to traditional statistical methods.

Figure 3 Predictive Workflow of AI Models Integrating Genomic and Clinical Data for Cancer Prognosis.

3.1 Risk Prediction Models

AI-driven risk prediction models have demonstrated superior performance compared to conventional prognostic tools. For instance, Kourou et al. (2015) developed several machine learning (ML) classifiers capable of predicting breast cancer survival with accuracy exceeding 85%, outperforming traditional regression models. Likewise, Lu et al. (2019) constructed a hybrid AI model integrating clinicopathological and genomic features, which achieved a C-index of 0.78 for predicting breast cancer recurrence. In another notable example, Wang et al. (2020) used deep learning on histopathological data to predict recurrence risk in colorectal cancer, achieving an area under the curve (AUC) of 0.92, significantly surpassing manual assessment. These predictive models not only assist oncologists in identifying high-risk patients but also enable risk-adapted treatment decisions, improving individualized care.

3.2 Prognostic Modelling

To determine the overall survival in glioblastoma patients by using deep learning (DL), histopathological images and genomic profiles were integrated by Mobadersany et al. (2018). This model offered a high amount of Prognostic accuracy in compare to the conventional methods, which emphasizes the ability of AI to holding complex datasets for providing predictions more perfectly.

4. Personalized Medicine

Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare treatments to the individual characteristics of each patient. This innovative method considers the genetic makeup, environment, and lifestyle of individuals to customize therapeutic strategies. Artificial Intelligence (AI) plays a transformative role in personalized medicine by leveraging advanced algorithms and vast datasets to tailor healthcare treatments to individual patients. AI algorithms analyse genetic data to identify mutations and variations that influence disease risk and treatment response.

4.1 Genetic and Genomic Analysis

AI algorithms are transforming genomic profiling by identifying driver mutations, predicting tumor evolution, and discovering targetable biomarkers with high precision. Machine learning models enable automated interpretation of next-generation sequencing (NGS) data, reducing manual analysis time and minimizing interpretation errors. For example,

Khorrami et al. (2021) demonstrated that deep learning applied to genomic–radiomic data could predict EGFR mutation status in lung cancer non-invasively, achieving accuracy above 85%, reducing reliance on invasive tissue biopsies. Similarly, clinical decision support systems such as IBM Watson for Oncology evaluate patient-specific genomic alterations to suggest evidence-based targeted therapies, improving oncologist decision-making consistency and treatment confidence (Chung et al., 2019). These advancements emphasize AI's pivotal role in accelerating biomarker discovery and supporting precision-targeted therapy selection.

4.2 Drug Sensitivity and Resistance

AI has made a crucial improvement in the area of predicting drug response. To determine the fruitfulness of targeted therapies in patients with non-small cell lung cancer, especially those with the mutations in EGFR, Erdem et al. (2020) designed a machine learning model. Such predictive models are significant for determining the most helpful treatment regimens for each and every patient.

Figure 4 Personalized drug screening and precision oncology applications

4.3 Patient-Specific Treatment Optimization

AI-driven algorithms are now used to optimize the sequence and timing of treatments including immunotherapy, chemotherapy, and radiation. Reinforcement learning tools evaluate real-time patient data to adjust therapy plans dynamically (Shaikh et al., 2022).

This adaptability is crucial because:

- tumors evolve under treatment pressure
- patient physiology changes during therapy
- immune response varies over time

Thus, AI enables continuously updated treatment plans, ensuring patients always receive the most beneficial intervention strategy.

5. Optimization of Radiation Therapy

Radiation therapy, a cornerstone in the treatment of cancer, utilizes high doses of radiation to kill cancer cells or inhibit their growth. This therapy functions by causing damage to the DNA of cancer cells, ultimately preventing them from dividing and proliferating. The damaged cells gradually die and are eliminated by the body. There are several types of radiation therapy, including External Beam Radiation Therapy (EBRT), which involves directing high-energy rays from outside the body to target the tumor, and Internal Radiation Therapy (brachytherapy), where a radiation source is placed inside the body near the cancerous area. Another method is Systemic Radiation Therapy, where radioactive substances are administered orally or intravenously to target cancer cells throughout the body. The precision of radiation therapy has significantly improved with technological advancements, enabling the targeted treatment of tumors while minimizing damage to surrounding healthy tissues. This approach not only increases the effectiveness of cancer treatment but also reduces the likelihood of side effects. Radiation therapy can be used alone or in combination with other treatments such as surgery and chemotherapy, making it a versatile and vital tool in the fight against cancer. While the therapy has its side effects, such as fatigue and skin changes, these are typically temporary and manageable, making radiation therapy a cornerstone in modern oncology for its efficacy and targeted approach. Radiation therapy is a foundation of cancer treatment and AI has effectively evolved its accuracy, precision and effectiveness.

5.1 Adaptive Radiotherapy

Adaptive Radiotherapy (ART) introduces modified radiation doses in real time on the basis of tumor dynamics. Men et al. (2019) exhibited the usefulness of deep learning algorithms in upgrading ART which leads to more accurate targeting and reduced amount of toxicity. This versatile approach jump forward in reducing the damage to surrounding health issues.

5.2 Treatment Planning and Dose Calculation

To improve dose calculation and planning of the treatment, AI has also been introduced in Oncology. Jiang et al. (2019) utilized a neural network model to upgrade intensity-modulated radiotherapy (IMRT), offering a depletion in unfavorable effects for head and neck cancer patients. These advancements emphasizes the role of AI in increasing the precision in radiation therapy.

5.3 Toxicity Prediction and Patient Safety

AI can also forecast **treatment-induced toxicities**, a critical step toward safer therapy delivery. Predictive models developed by **Dean et al. (2020)** used patient-specific anatomical

Figure 5 AI-Based Workflow for Radiation Treatment Planning and Adaptive Dose Calculation

and dosimetric data to estimate **risk of radiation pneumonitis** in lung cancer, improving preventive care decisions.

This predictive approach helps clinicians tailor therapy intensity to minimize side effects such as mucositis, fibrosis, or secondary malignancies, thereby enhancing patients' quality of life post-treatment.

5.4 Limitations and Ethical Challenges

Despite major advancements, AI-based radiation therapy faces key challenges:

- **Data Standardization:** Heterogeneous imaging formats hinder cross-center model validation.
- **Computational Complexity:** Deep learning algorithms demand high-performance hardware, increasing cost and maintenance.
- **Interpretability Issues:** Black-box dose-prediction models are difficult to verify clinically.
- **Ethical Considerations:** Automation in dose delivery raises accountability questions in case of treatment errors (Topol, 2019). Addressing these limitations requires **robust validation**, transparent modeling, and **human oversight** in clinical decision-making.

In summary, AI-driven radiation therapy represents a pivotal advancement toward **personalized, adaptive, and safer cancer treatment**. By automating complex planning tasks and enabling real-time dose adjustment, AI bridges the gap between technology and precision medicine in modern oncology.

6. AI in Drug Discovery

Drug discovery is a complex and multi-faceted process aimed at identifying new therapeutic compounds that can effectively treat diseases. It begins with the identification of a biological target, such as a protein or gene involved in a disease pathway. Researchers then screen large libraries of chemical compounds to find potential candidates that interact with the target. These initial hits are refined through various stages of optimization to enhance their efficacy, selectivity, and safety. This involves detailed preclinical studies, including in vitro and in vivo testing, to assess the compound's pharmacokinetics (how it moves through the body) and pharmacodynamics (its effects on the body). Once a promising candidate is identified, it moves into clinical trials, which are conducted

in phases to test its safety, dosage, and effectiveness in humans. The entire process is highly collaborative, involving scientists from multiple disciplines such as biology, chemistry, pharmacology, and medicine, and can take many years and substantial financial investment to bring a new drug to market. Despite the challenges, advancements in technology and a deeper understanding of disease mechanisms continue to drive innovations in drug discovery, offering hope for more effective treatments for a variety of conditions.. By rapidly identifying the target and determining drug efficiency, Drug discovery is estimated as a detailed process which is revolutionized by AI.

6.1. Identifying New Drug Candidates

AI models, for example, generative adversarial networks (GANs), have been designed to generate possible drug candidates with the addition of individual desired properties. Zhavoronkov et al. (2019) successfully utilized AI to find out DDR1 kinase inhibitors which has successfully decreased the required time for initial screening. In oncology, AI-driven molecular design tools are being used to explore **protein-ligand interactions** and predict **binding affinities**, accelerating the identification of potential anticancer compounds (Paul et al., 2022).

6.2 Predicting Drug Efficacy and Side Effect

To predict the drug effectiveness and its potential side effects, AI also exhibits a vital role. For example, Alphafold which has been developed by Jumper et al. (2021) ,transformed protein structure prediction in huge amount. Not only helped in the determination of new drug targets, but also evolved the whole drug development procedure.

6.3 Drug Repurposing and Combination Therapy Optimization

One of the most cost-effective uses of AI in oncology is **drug repurposing**, where existing drugs are analyzed for new therapeutic uses. Deep learning models can screen existing drug databases (e.g., DrugBank, PubChem) to identify new anticancer indications for approved molecules.

For example, **Zeng et al. (2021)** employed graph convolutional networks (GCNs) to repurpose non-oncology drugs as potential agents for pancreatic and colorectal cancers, significantly reducing discovery costs.

AI also supports **combination therapy optimization**, predicting synergistic effects among drugs to overcome resistance in aggressive cancers (Kuenzi et al., 2020).

6.4 Challenges and Ethical Considerations in AI-Based Drug Discovery

Despite its transformative promise, AI-driven drug discovery faces several **critical challenges**:

- **Data Quality and Availability:** Many biological datasets are incomplete, biased, or lack standardization, limiting model accuracy.
- **Validation Gap:** AI predictions often require **experimental and clinical validation**, which remains a bottleneck for real-world application.
- **Interpretability:** Deep learning models often function as "black boxes," making it difficult to justify molecule selection to regulatory bodies.
- **Ethical Concerns:** Ownership of AI-generated molecules, data privacy in patient-derived models, and potential misuse of predictive algorithms raise regulatory and ethical questions (Vayena et al., 2021).

Overcoming these barriers requires **multidisciplinary collaboration** among computational scientists, pharmacologists, and ethicists to ensure transparent, validated, and ethically governed AI systems.

7. Improved Patient Management

Improved patient management refers to the implementation of strategies and practices designed to enhance the quality of care and overall patient experience within healthcare systems. Central to this approach is the use of advanced technologies, such as electronic health records (EHRs), telemedicine, and AI-powered diagnostic tools, which streamline communication between patients and healthcare providers. These technologies facilitate timely access to patient information, enable more accurate diagnoses, and allow for personalized treatment plans tailored to individual needs. Improved patient management also emphasizes the importance of patient engagement, encouraging active participation in their own care through educational resources, health tracking apps, and consistent follow-up care. This holistic approach not only improves clinical outcomes but also boosts patient satisfaction by ensuring that care is coordinated, efficient, and patient-centred. Ultimately, improved patient management aims to provide high-quality, efficient, and compassionate care that meets the evolving needs of patients in a dynamic healthcare landscape. By offering real-time monitoring and personalized and improved care, tools, powered by AI are improving the patient management system.

7.1 Virtual Assistants and Symptom Monitoring

AI-authored virtual assistants, such as Chatbots, have been accomplished to help in symptom observation and patient education. By using these tools Bickmore et al. (2018) observed upgraded patient engagement and symptoms reporting on time. By delivering regular monitoring and timely interventions, Esteva et al. (2021) has shown that the potentiality of AI in minimizing hospital readmissions.

7.2 Personalized Follow-Up Care

AI models integrate longitudinal patient data—such as electronic health records (EHRs), genomics, and treatment histories—to design **personalized follow-up schedules** and **predictive care models**.
Shameer et al. (2017) proposed AI-driven predictive frameworks that stratify patients by recurrence risk and optimize surveillance frequency. This adaptive system allows oncologists to **prioritize high-risk patients** and **reduce redundant imaging or testing**, thereby optimizing both cost and resource allocation.

Furthermore, AI-powered **digital twins**—virtual models that simulate an individual's disease trajectory—are being explored for predicting **treatment response and disease relapse**, helping to preemptively adjust care strategies (Björnsson et al., 2022).

7.3 Ethical, Validation, and Data Governance Challenges

While AI-enhanced patient management holds great promise, it also introduces important **ethical and operational challenges**:

- **Bias in Training Data:** AI models may reflect historical healthcare inequalities, leading to skewed recommendations or overlooked populations (Obermeyer et al., 2019).
- **Data Privacy:** Continuous symptom tracking and wearable integration generate sensitive health data that must comply with **GDPR** and **HIPAA** standards.
- **Validation and Trust:** Clinical validation of AI monitoring systems is limited; many models lack real-world testing across diverse populations.
- **Patient–Clinician Relationship:** Over-reliance on automation may reduce personal interaction and empathy—vital components in cancer care.

Therefore, implementing AI-based patient management solutions requires **rigorous ethical oversight**, transparent data policies, and **human supervision** to ensure accountability and trust.

AI is redefining patient management from a static, hospital-centred system to a **dynamic, data-driven, and patient-centred ecosystem**. By combining predictive modelling with real-time monitoring, AI enables **continuous care**, early intervention, and higher patient satisfaction. However, success will depend on addressing data ethics, inclusivity, and model interpretability to ensure **safe and equitable AI integration** in clinical practice.

8. Future Perspectives

In oncology, the future of AI looks more dedicating, in various fields, composed for efficient improvements. The future of Artificial Intelligence (AI) in the field of oncology holds immense potential, promising significant advancements across various domains dedicated to enhancing the efficacy and efficiency of cancer care. AI is poised to revolutionize the way cancer is diagnosed, treated, and managed, offering unprecedented opportunities for precision medicine. In diagnostic imaging, AI algorithms, particularly those utilizing deep learning and convolutional neural networks, have demonstrated exceptional accuracy in detecting cancerous lesions from radiographic images, surpassing traditional methods. This improvement not only leads to earlier and more accurate diagnoses but also reduces the likelihood of false positives and negatives, streamlining the diagnostic process.

Moreover, AI's role in treatment planning is transformative. By analysing vast amounts of clinical data, AI can assist oncologists in developing personalized treatment plans tailored to the genetic and molecular profiles of individual patients. This ensures that patients receive the most effective therapies, minimizing adverse effects and improving overall outcomes. AI-driven predictive models can also identify patients who are at higher risk of treatment-related complications, allowing for proactive management and intervention.

Additionally, AI is enhancing the drug discovery process, identifying novel therapeutic targets and predicting the efficacy of potential drugs with greater speed and accuracy than traditional methods. This accelerates the development of new cancer treatments and improves the likelihood of successful clinical trials.

In the realm of patient management, AI-powered tools enable continuous monitoring and real-time adjustments to treatment plans based on the patient's response and evolving condition. This dynamic and responsive approach ensures that care is always optimized for the best possible outcomes.

Overall, the future of AI in oncology is dedicated to making significant strides in improving efficiency and effectiveness across various fields, ultimately transforming cancer care and offering hope for better patient outcomes.

8.1 Integration with Emerging Technologies

The combination of AI with technologies, for example, Robotics and Wearable devices could improve cancer treatment. Vayena et al. (2018) explained the mechanism of Wearable devices which offer uninterrupted data about patient health, helps in early detection of complications.

8.2 Ethical and Regulatory Challenges

Instead of its potential, the distribution of AI in clinical purpose encounters ethical and regulatory challenges. Obermeyer et al. (2019) mentioned out concerns regarding prejudices in AI models, while Topol (2019) established the necessity of transparency and robust regulatory frameworks to providing the surety of patients' safety.

8.3 Future Challenges and Research Directions

Despite promising progress, several key challenges remain:

- **Data Fragmentation:** Lack of standardized data formats across hospitals limits interoperability and model training.
- **Bias and Fairness:** Current AI systems may perpetuate healthcare disparities unless trained on diverse, representative datasets.
- **Interpretability and Validation:** Many high-performing models remain "black boxes," lacking interpretability and reproducibility in clinical trials.
- **Human–AI Collaboration:** The goal should be to **augment**, not replace, clinicians—ensuring AI complements medical expertise rather than substitutes it.
- **Sustainability:** High computational costs and carbon footprints from large AI models demand greener, resource-efficient algorithms.

Future research must emphasize **explainable AI (XAI)**, **cross-cultural validation**, and **interdisciplinary collaboration** to ensure equitable, transparent, and sustainable AI-driven oncology.

AI's trajectory in oncology is undeniably transformative. As technology, policy, and ethics align, the next decade will witness AI evolving from a supportive tool to a **core pillar of precision oncology**. With responsible development and rigorous validation, AI will empower clinicians to deliver **smarter, safer, and more compassionate cancer care** worldwide.

9. Conclusion

Artificial Intelligence (AI) has emerged as a transformative force in oncology, fundamentally redefining how cancers are detected, diagnosed, and managed. Through the integration of **machine learning, deep learning, and data analytics**, AI has enabled unparalleled precision in cancer imaging, treatment planning, drug discovery, and patient monitoring.

By analyzing high-dimensional datasets encompassing radiomic, genomic, and clinical variables, AI systems have demonstrated superior diagnostic accuracy and prognostic capability compared to traditional approaches (McKinney et al., 2020; Mobadersany et al., 2018). Furthermore, predictive analytics has made it possible to **anticipate treatment outcomes and personalize therapies**, ensuring that each patient receives an optimized, evidence-based intervention tailored to their unique molecular and physiological profile (Kourou et al., 2015; Esteva et al., 2021).

AI's role in **drug discovery** and **treatment optimization** has accelerated the identification of therapeutic targets and reduced the time required for clinical translation (Zhavoronkov et al., 2019; Jumper et al., 2021). In radiation therapy, AI-enhanced dose calculation and adaptive planning have elevated treatment precision and minimized normal tissue toxicity (Jiang et al., 2019; Lambin et al., 2019). Similarly, in patient management, AI-powered virtual assistants and predictive models have revolutionized follow-up care and patient engagement, contributing to improved quality of life and reduced hospital readmissions (Bickmore et al., 2018; Shameer et al., 2017).

However, the full potential of AI can only be realized by addressing persistent challenges related to **data bias, ethical considerations, validation, and interpretability** (Obermeyer et al., 2019; Vayena et al., 2021). Ethical frameworks ensuring fairness, transparency, and accountability must be embedded into every stage of AI development and deployment.

In summary, AI stands at the forefront of a new era in cancer care — one characterized by **precision, personalization, and predictive intelligence**. The successful integration of AI into oncology depends not only on technical

advancement but also on **interdisciplinary collaboration, regulatory evolution, and sustained ethical governance**. With continued innovation and responsible application, AI has the potential to **transform cancer care globally**, enabling earlier detection, smarter treatment, and better patient outcomes for generations to come.

10. References

Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., ... & Shetty, S. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low- dose chest computed tomography. Nature medicine, 25(6), 954-961.

Bickmore, T. W., Schulman, D., & Sidner, C. L. (2011). A reusable framework for health counseling dialogue systems based on a behavioral medicine ontology. Journal of biomedical informatics, 44(2), 183-197.

Bulten, W., Pinckaers, H., van Boven, H., Vink, R., de Bel, T., van Ginneken, B., ... & Litjens, G. (2020). Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. The Lancet Oncology, 21(2), 233-241.

Chung, I. Y., Jung, M., Lee, S. B., Lee, J. W., Park, Y. R., Cho, D., ... & Ahn, S. H. (2019). An assessment of physical activity data collected via a smartphone app and a smart band in breast cancer survivors: observational study. Journal of medical Internet research, 21(9), e13463.

Coudray, N., Ocampo, P. S., Sakellaropoulos, T., Narula, N., Snuderl, M., Fenyö, D., ... & Tsirigos, A. (2018). Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning. Nature medicine, 24(10), 1559-1567.

Erickson, B. J., Korfiatis, P., Akkus, Z., & Kline, T. L. (2017). Machine learning for medical imaging. radiographics, 37(2), 505-515.

Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. nature, 542(7639), 115-118.

Jiang, Y., Liang, X., Han, Z., Wang, W., Xi, S., Li, T., ... & Li, R. (2021). Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. The Lancet Digital Health, 3(6), e371-e382.

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., ... & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. nature, 596(7873), 583-589. Kourou, K., et al. (2015). Computational and Structural Biotechnology Journal.

Lambin, P., Lieverse, R., Baumann, M., & Ebert, N. (2019). Will immunotherapy really change radiotherapy?. Lancet oncology, 20(12), 1642-1644.

Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., ... & Lu, X. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(6), 806-815.

McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., ... & Shetty, S. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577(7788), 89-94. Beyer, T., Bailey, D. L., Birk, U. J., Buvat, I., Catana, C., Cheng, Z., ... & Moser, E. (2021). Medical Physics and imaging–A timely perspective. Frontiers in Physics, 9, 634693.

Mobadersany, P., Yousefi, S., Amgad, M., Gutman, D. A., Barnholtz-Sloan, J. S., Velázquez Vega, J. E., ... & Cooper, L. A. (2018). Predicting cancer outcomes from histology and genomics using convolutional networks. Proceedings of the National Academy of Sciences, 115(13), E2970-E2979.

Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447-453.

Roy, S., Guha, P., & De, D. (2025). Harnessing AI for enhanced cancer care: Current applications and future prospects. *Brainwave: A Multidisciplinary Journal*, *6*(4), 1186–1199.

Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., ... & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688- 702.

Sung, H., Hyun, N., Leach, C. R., Yabroff , K. R., & Jemal, A. (2020). Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. Jama, 324(24), 2521-2535.
.
Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature medicine, 25(1), 44-56.

Vayena, E., Ferretti, A., Benatar, S., & Brock, G. (2021). Big Data and Artificial Intelligence for Global Health. Global Health: Ethical Challenges, 429.

Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., ... & Aspuru-Guzik, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature biotechnology, 37(9), 1038-1040.

Contributors

Subhajit Roy
Former Student, Master of Biotechnology, Department of Biotechnology, Brainware University, West Bengal, India.
Email: mr.sroy2002@gmail.com

Payal Guha
Former Student, Master of Biotechnology, Department of Biotechnology, Brainware University, West Bengal, India.
Email: payalguha381@gmail.com

Dr. Debapriya De
Assistant Professor, Department of Biotechnology, Brainware University, West Bengal, India.
Email: ddd.bt@brainwareuniversity.ac.in